Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7315757 | 0.90 | HDAC6 (0.53) | HDAC1HDAC6HDAC3HDAC10HDAC8 | |
| SCHEMBL7322974 | 0.90 | HDAC6 (0.43) | HDAC1HDAC6HDAC3HDAC10HDAC8 | |
| SCHEMBL7314103 | 0.89 | HDAC6 (0.54) | HDAC1HDAC6HDAC3HDAC10HDAC8 | |
| SCHEMBL7321224 | 0.88 | HDAC6 (0.47) | HDAC1HDAC6HDAC3HDAC10HDAC8 | |
| SCHEMBL7321674 | 0.86 | HDAC6 (0.48) | HDAC1HDAC6HDAC3HDAC10HDAC8 | |
| SCHEMBL7317140 | 0.82 | HDAC6 (0.51) | HDAC1HDAC6HDAC3HDAC10HDAC8 | |
| SCHEMBL7315855 | 0.81 | HDAC6 (0.52) | HDAC1HDAC6HDAC3HDAC10HDAC8 | |
| SCHEMBL7314618 | 0.81 | HDAC6 (0.47) | HDAC1HDAC6HDAC3HDAC10HDAC8 | |
| SCHEMBL7322358 | 0.81 | HDAC6 (0.46) | HDAC1HDAC6HDAC3HDAC10HDAC8 | |
| SCHEMBL7325410 | 0.78 | HDAC6 (0.47) | HDAC1HDAC6HDAC3HDAC10HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2023-03-30 | — | — | US | disclosed |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| EP-0901465-B1 | COMPOUNDS WITH ANTI-INFLAMMATORY AND IMMUNOSUPPRESSIVE ACTIVITIES | ITALFARMACO SPA (IT) | 2000-09-27 | — | — | EP | disclosed |
| US-6034096-A | Compounds with anti-inflammatory and immunosuppressive activities | ITALFARMACO S.P.A. (IT) | 2000-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885HDAC6 10/4885HDAC3 1/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC1 2/4885HDAC6 10/4885HDAC3 1/4885 |
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC2, HDAC1 | HDAC1 3/4885HDAC6 10/4885HDAC3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.